Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03146663 · ClinicalTrials.gov registry record · Phase 2
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
A Phase 2 study, sponsored by NuCana.
- Terminated
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT03146663: Clinical Trial Phase 2 study, sponsored by NuCana.
NCT03146663 is a Phase 2 study that was terminated before completion, run by NuCana. The registered enrollment target is 53 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03146663, a Phase 2 study, was terminated before completion, sponsored by NuCana.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
This study was designed to evaluate the effect of two dose levels of NUC-1031 (500 mg/m2 and 750mg/m2) in patients with ovarian cancer. The primary objective was to determine the anti-tumor activity of NUC-1031 at the selected dose level (500 mg/m2 or 750 mg/m2).
Primary Outcome
Best overall response to study treatment, as assessed by blinded independent central review according to RECIST v1.1, in the evaluable population of patients who received at least one dose of study treatment and had measurable disease at baseline. Complete Response (CR): disappearance of all target and non-target lesions, normalization of tumor markers, and pathological lymph nodes must have short axis measurements \<10 mm. Partial Response (PR): ≥30% decrease in the sum of measures of target
Interventions
- DRUG NUC-1031 500 mg
- DRUG NUC-1031 750mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2017-09-28 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 2 |
Why NCT03146663 stopped before completion
NCT03146663 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 2 interventions - of which NUC-1031 500 mg is the first listed.
NCT03146663 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03146663 about?
NCT03146663 is a clinical study titled "NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer". This study was designed to evaluate the effect of two dose levels of NUC-1031 (500 mg/m2 and 750mg/m2) in patients with ovarian cancer. The primary objective was to determine the anti-tumor activity of NUC-1031 at the selected dose level (500 mg/m2 or 750 mg/m2).
What is the current status of trial NCT03146663?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2017-09-28. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03146663?
The interventions under investigation include: NUC-1031 500 mg (DRUG), NUC-1031 750mg (DRUG).
Who is sponsoring clinical trial NCT03146663?
This trial is sponsored by NuCana, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03146663's enrollment target sits among peer trials
53 1171st of 2000 higher than 820 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI